ABCA9 and colorectal carcinoma: Thus, ABCA9 polymorphisms were associated with reduced survival in CRC patients who received oxaliplatin-based chemotherapy [69], whereas ABCA13 overexpression may be associated with improved outcomes in CRC, due to an increment in the disease-free interval of patients treated by adjuvant chemotherapy which have ABCA13 upregulated in tumor tissues [59].